Considering that hepatic FXR activation is believed to ameliorate liver disease [30], it is surprising that patients with decompensated cirrhosis—having a worse prognosis than patients with cACLD [31]—showed higher expression levels of FXR and SHP. This evidence concerns the gene NR1H4 and liver disorder.